Evicenter
MarkdownMedical informationP&T meetings

Claseprubart (DNTH103)

Generalized myasthenia gravis

Launch
Not announced
Last updated
120 sources

Section 2 of 6

Executive summary

4 evidence topics · 30 sources

Clinical benefits of Claseprubart

Burden of Generalized myasthenia gravis

Summary

The US estimates are for myasthenia gravis as a whole. In 2021 US claims and electronic health records, the diagnosed prevalence was 37.0 per 100,000 persons and the incidence 3.1 per 100,000 persons, and a separate claims analysis estimated approximately 82,715 US adults living with myasthenia gravis in 2021. A global meta-analysis of 63 articles estimated a prevalence of 12.4 (95% CI 10.6 to 14.5) per 100,000 population. Generalized disease specifically was measured in one cohort, where the 2019 prevalence was 11.18 and the incidence 2.95 per 100,000 population. Up to 80% of patients with ocular onset develop generalized symptoms, usually within two years, and approximately one third of patients with generalized disease have an exacerbation in a given year. Among hospitalizations from 2010 to 2019, the in-hospital mortality rate averaged 1.8%, and mortality averaged 5.0% among patients aged 65 years or older; in a separate cohort, 5-year overall survival was 75%, declining to 39% among those with crisis.

Among 841 participants from seven countries, mean baseline EQ-5D-5L utility was 0.817, 0.766, 0.648, and 0.530 for MGFA classes I to IV; in a larger MRW cohort (n = 1859), average EQ-5D-5L utility was 0.739, compared with 0.843 in POPUP. In Komodo Research data from 2017 to 2023, mean annual all-cause total health care costs in adults with newly diagnosed generalized myasthenia gravis were $58,341, compared with $14,469 in the non-MG cohort, with 59.3% of the difference driven by pharmacy costs (mostly immunoglobulin). Annual all-cause costs were $76,381 with any glucocorticoid use and $35,309 without, and mean monthly costs were $17,330 in a subgroup with exacerbation or crisis.

Claseprubart efficacy and safety

Summary

MaGic is a phase 2, randomized, double-blind, placebo-controlled trial that enrolled 65 participants with AChR antibody-positive generalized myasthenia gravis, randomized 1:1:1 to claseprubart 300 mg or 600 mg subcutaneously every 2 weeks or placebo for 13 weeks, followed by a 52-week open-label extension. Its primary endpoint was safety; efficacy measures were secondary or exploratory, and P values were one-sided. Sixty-three of 65 participants completed the randomized period. At week 13, the mean change from baseline in MG-ADL was –4.6 with 300 mg and –5.4 with 600 mg, compared with –2.8 with placebo, placebo-adjusted differences of –1.8 (P=0.0113) and –2.6 (P=0.0006). The placebo-adjusted change in QMG was –2.4 (P=0.0144) and –2.5 (P=0.0111). MG-ADL minimal symptom expression was achieved by 37% (7/19) with 300 mg and 14% (3/22) with placebo (P=0.0550). The press release reported placebo-adjusted MGC changes of –5.6 and –5.5 (P=0.0008), while the later poster reported –4.1 and –4.3 (P=0.0023 and P=0.0016). Participants who continued claseprubart in the open-label extension maintained their improvement in MG-ADL, QMG, and MGC through 65 total weeks of treatment.

During the randomized period, infections occurred in 10 of 22 placebo participants (45.5%), 5 of 21 (23.8%) receiving 300 mg, and 6 of 22 (27.3%) receiving 600 mg. No participant receiving claseprubart had a treatment-related serious adverse event, and none discontinued for an adverse event; the only treatment-related serious infection occurred in the placebo arm. Injection site reactions occurred in 2 participants in each claseprubart arm, all mild to moderate. Among participants who were antinuclear antibody negative at baseline, 1 of 17 (5.9%) receiving 300 mg and 8 of 22 (36.4%) receiving 600 mg tested positive at a titer of at least 1:320 during the randomized period, and no symptoms indicative of autoimmune activation were reported. In the open-label extension (n=60), the poster table lists 1 participant (1.7%) under related serious adverse events, 1 (1.7%) under related serious infections, and 1 (1.7%) under discontinuation due to a related adverse event; its footnotes describe a participant with influenza who recovered and restarted claseprubart (not considered related by the sponsor) and a participant with arthritis. No meningococcal infections occurred, and one death from a cardiovascular event during the safety follow-up period was deemed unrelated to claseprubart.

These data are from a phase 2 trial with 21 to 22 participants per arm and are reported in company press releases and presentations and in congress posters and abstracts; no peer-reviewed full article reporting the trial was identified. The phase 3 EMERGE trial, comparing claseprubart 300 mg every 2 or 4 weeks with placebo on MG-ADL change at Week 17, began in June 2026 and has no results.

Budget impact of Claseprubart

Summary

No price for claseprubart has been announced and no budget impact model of claseprubart has been published. A company investor presentation states an assumed average biologic net price per patient of approximately $400,000 per year for the generalized myasthenia gravis market.

Published cost-effectiveness analyses include evaluations of eculizumab and efgartigimod. In the 2021 ICER evaluation over a 2-year horizon, eculizumab at an estimated annual cost of $653,100 had an incremental cost-effectiveness ratio of $5,210,000 per QALY/evLYG, and efgartigimod at a placeholder price of $418,400 had $2,076,000 per QALY/evLYG; the health benefit price benchmark was $13,200 to $19,400 for eculizumab and $18,300 to $28,400 for efgartigimod, and 8.8% of the eligible population could be treated with efgartigimod at the placeholder price without passing ICER's budget impact threshold. A Markov model with a lifetime horizon estimated $3,338,000 per QALY gained for eculizumab and found that eculizumab and efgartigimod would need discounts of 93.01% and 88.34% of the base-case price to be cost-effective.

Conclusions

Summary

An estimated 82,715 US adults were living with myasthenia gravis in 2021, and up to 80% of patients with ocular onset go on to develop generalized symptoms, usually within two years. After weighting, patients with generalized myasthenia gravis had more than 4-fold higher healthcare costs than non-gMG controls ($5420 compared with $1298 per patient per month), with higher costs among those with exacerbation or crisis and among those with any glucocorticoid use. 10% to 20% of patients continue to have long-standing moderate or severe weakness after treatment with at least two different immunosuppressive drugs at high doses, and upward of thirty percent of patients do not benefit from complement inhibition. Soliris increases the risk of serious meningococcal infections and, like Zilbrysq, is available only through a REMS program. ICER estimated incremental cost-effectiveness ratios of $5,210,000 per QALY/evLYG for eculizumab and $2,076,000 per QALY/evLYG for efgartigimod at a placeholder price.

Claseprubart is an investigational classical pathway inhibitor targeting active C1s, administered by subcutaneous injection. In the 65-participant phase 2 MaGic trial, both doses improved MG-ADL and QMG compared with placebo at week 13; participants who continued claseprubart showed sustained improvement at open-label extension week 52 (65 total weeks on treatment); no participant receiving claseprubart had a treatment-related serious adverse event or discontinued for an adverse event during the randomized period; and among participants antinuclear antibody negative at baseline, 1 of 17 (5.9%) receiving 300 mg and 8 of 22 (36.4%) receiving 600 mg tested positive at a titer of at least 1:320, with no symptoms indicative of autoimmune activation. The phase 3 EMERGE trial began in June 2026, with top-line results expected in the second half of 2028. No phase 3 results, peer-reviewed full article, price, or budget impact model for claseprubart was identified, so comparative efficacy and cost against complement C5 inhibitors and FcRn blockers cannot yet be assessed.